
Life at the Limit: The Economics of Cheating Death
What a year of life is actually worth, how to bend the aging curve, and why the shape of the longevity prize may matter more than its size.
Read articleEssays on science and company building. Conversations with the people pushing both forward.

What a year of life is actually worth, how to bend the aging curve, and why the shape of the longevity prize may matter more than its size.
Read article
Prime Movers Lab leads Series A for massively parallel multi-modality drug discovery platform company Zafrens.The speed of drug discovery is limited by our ability to generate experimental data. To design a…
Read article
Prime Movers Lab leads $19M Series A round for organ regeneration cell therapy startup LyGenesis.The future of cell therapy and transplant medicine could have a new and unlikely hero: a patient’s own lymph…
Read articleAt Prime Movers Lab, we back scientific entrepreneurs progressing breakthrough science with the potential to impact billions of lives. PML…
Read on Medium ↗Prime Movers Lab leads limb regeneration startup Morphoceuticals’ Seed Round with Juvenescence.
Read on Medium ↗Prime Movers Lab leads Series A in leading tissue engineering company Dimension Inx.
Read on Medium ↗Venture capital investing is a bit like walking around at midnight, or blindfolded. You know where you want to go. You are physically able…
Read on Medium ↗Two things in life are certain: death and taxes. Or so the saying goes. A growing number of scientists are chipping away at the very…
Read on Medium ↗
On this episode, our guest is economist Paul Kohlhaas, co-founder and CEO of Molecule and co-author of the VitaDAO whitepaper. We’ll head to Berlin, Germany, where Paul and his team of scientists, engineers,…
Read episode notes
On this episode, Ochre Bio co-founders join us to discuss turning discarded organs into a goldmine of biological insight with deep phenotypics that enables the company to pan for fine-grained expression of all…
Read episode notes
On this episode we’ll meet Dr. Daniel Levner, co-founder and Chief Technology Officer at Emulate, a company commercializing technology to remake human biology from the ground up using small rubbery…
Read episode notes
On this episode we’ll meet Thomas Fleming, Oxford-trained engineer, and co-founder and Chief Operating Officer of Arctoris a company that has developed a fully-autonomous drug discovery laboratory. Founded in…
Read episode notes
On this episode we’ll take a walk, literally, with the founder and CEO of Rune Labs, Brian Pepin. Brian previously led electroceuticals development at GSK-backed Galvani, built a glucose-sensing contact lens…
Read episode notes
In flash, a stroke can have devastating consequences. Improving recovery outcomes will require new thinking. My grandmother’s stroke years ago shook my family. I saw her in fits over the loss of precious…
Read episode notes
How do you make a molecule? We’ve talked before on the TomorrowScale podcast about the challenges facing chemists–the “synthesis barrier.” The creation of novel materials and the discovery of small molecule…
Read episode notes
The development of brain-machine or brain-computer interfaces (BCIs) approaches an inflection point; not just in the pace of BCI progress, but also the capabilities and willingness to explore the field of…
Read episode notes
How do you build biology? Simple: DNA to RNA to proteins, right? Not so fast. Each one of your trillions of cells are themselves little factories, constantly producing various peptides and proteins that your…
Read episode notes
On this episode Oklo co-founders Jacob DeWitte and Caroline Cochran join us to discuss what it took to get their startup to this point in development of the first advanced nuclear fission power plant; how a…
Read episode notes
At the center of every clinical trial is a group of patients, each with a medical condition that we seek to understand more about through interacting with those patients directly. Startups like Sanguine…
Read episode notes
On this episode we’ll meet biophysicist, machine learning researcher, and CEO of UnlearnAI Dr. Charles Fisher. He and the team at Unlearn have the goal to build the entire biomedical machine learning stack,…
Read episode notes
On this show we talk a lot about the opportunity and the promise of innovation. It is incredibly difficult, however, to study the actual impact of those new technologies. In healthcare, we do have some chance…
Read episode notes
On this episode, we’ll speak with one of the principal researchers on the Wolfram Physics Project, Jonathan Gorard. We’ll discuss how they plan to actually implement their “fundamental theory of the universe”…
Read episode notes
Dr. Chang Liu, assistant professor of biomedical engineering at the University of California, Irvine, has transformed traditional yeast culture methods into an engine to accelerate evolution in order to…
Read episode notes
In the beginning, there was chemistry. Well, not exactly. From those primordial reaction conditions … life emerged. But how? What separates chemistry from biology? How do we study the origin of life? What can…
Read episode notes
What does the future of scientific computing look like? Labs all over the world are racing to build chips based on our brains. But what can it do? And what will it be used for? On this episode, we’ll meet a…
Read episode notes
On this episode we sit down with star scientists from Netflix’s show ‘Pandemic,’ DistributedBio co-founder and CEO Jacob Glanville, and Centivax program lead and director of contract research Sarah Ives. We’ll…
Read episode notes
Drugs are getting smarter. A new wave of companies, including those founded by our guest, Matthew Scholz of Oisin Biotechnologies and OncoSenX, ride on recent advances in drug and gene delivery that are…
Read episode notes
The ability to visualize disease is vital to many parts of patient care. On this episode, we’ll meet AIQ Solutions, a company that is taking a long-term view of a patient’s response to cancer treatment using…
Read episode notes
Drug discovery is changing. Deep generative models, as being pioneered by our guest Dr. Alex Zhavoronkov, founder and CEO of InSilico Medicine, are able to generate entirely new molecules and even, as we’ll…
Read episode notes
On this episode, we’ll hear about Lodo and their plan to discover medicine from microbes. This is the TomorrowScale Podcast. Hosted by Justin Briggs. Lodo Therapeutics is a drug discovery company based in New…
Read episode notes
Vaccines save lives. Yet, despite concerted global efforts more than 1.5 million children die each year from vaccine preventable diseases. The Bill & Melinda Gates Foundation are at the center of this massive…
Read episode notes
On this episode, we’ll meet Melanie Matheu, Ph.D., a scientist turning light into life. Her company, Prellis Biologics, has developed what may be a defining technology for the bioprinting industry: A method to…
Read episode notes
Unanticipated results can lead to great discoveries. Zeakal is a company founded by turning such an unexpected outcome into a promising biotechnology company. We conducted multiple interviews between 3 cities,…
Read episode notes
What is the difference between an entrepreneur and a serial entrepreneur? Is there a difference? We dig into this question with a four-time hard tech entrepreneur. Mike Moradi is the co-founder and CEO of…
Read episode notes
The TomorrowScale Podcast is a series of conversations with the scientists and leaders who are building the future. I am very excited to announce that we are in production on the first episodes of the…
Read episode notes